Cargando…

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Younossi, Zobair M., Golabi, Pegah, Paik, James M., Henry, Austin, Van Dongen, Catherine, Henry, Linda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles: Steatohepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026948/ https://www.ncbi.nlm.nih.gov/pubmed/36626630 http://dx.doi.org/10.1097/HEP.0000000000000004

Ejemplares similares

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
por: Paik, James M, et al.
Publicado: (2020)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
por: Paik, James M., et al.
Publicado: (2023)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
por: Yan, Tingting, et al.
Publicado: (2023)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
por: Paik, James M., et al.
Publicado: (2019)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice
por: Locatelli, Irene, et al.
Publicado: (2014)

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
por: Zhu, Yuezhi, et al.
Publicado: (2023)

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
por: Kim, Kyung Eun, et al.
Publicado: (2023)

353. A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV-Infected Patients
por: Choe, Sunny, et al.
Publicado: (2019)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
por: Terai, Shuji, et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016
por: Arshad, Tamoore, et al.
Publicado: (2021)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oldbgqiuq05d0esob7t69i5kep